CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 60 enrolled
Drug / intervention
Bupropion +1 moredrug
Likely dose
Bupropion 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00621517
NCT00621517Phase 3Completed
CompareCT.gov

Bupropion and Restless Legs Syndrome

East Tennessee State University·interventional·Posted Feb 22, 2008·Updated Mar 6, 2019

In Brief

A Phase 3 clinical trial evaluating Bupropion and Placebo for Restless Legs Syndrome. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if bupropion will improve the symptoms of restless legs syndrome (RLS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRestless Legs Syndrome
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 22, 2008
Enrollment StartFeb 1, 2008
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 18.4 years ago

Interventions

Bupropiondrug

Partipants will receive 150 mg bupropion per night

Placebodrug

1 capsule nightly for six weeks